HealthDay - THURSDAY, July 21 (HealthDay News) -- New research finds that the targeted cancer drug Tarceva nearly triples the amount of time lung cancer patients survive without a recurrence and has fewer side effects than standard chemotherapy.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.